Lataa...
Safety of Immune Checkpoint Inhibitors in Patients with Cancer and Hepatitis C Virus Infection
BACKGROUND: The safety of immune checkpoint inhibitors (ICIs) in patients with hepatitis C virus (HCV) infection has not been studied in many cancers, as these patients were excluded from most ICI trials. This poses a degree of uncertainty when a patient with HCV is being considered for ICIs in the...
Tallennettuna:
| Julkaisussa: | Oncologist |
|---|---|
| Päätekijät: | , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
John Wiley & Sons, Inc.
2021
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8100564/ https://ncbi.nlm.nih.gov/pubmed/33655663 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/onco.13739 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|